Vor Biopharma Inc. (VOR)
NASDAQ: VOR · IEX Real-Time Price · USD
1.740
-0.140 (-7.45%)
At close: Apr 24, 2024, 4:00 PM
1.840
+0.100 (5.75%)
After-hours: Apr 24, 2024, 7:26 PM EDT
Vor Biopharma Stock Forecast
VOR's stock price has decreased by -62.09% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Vor Biopharma stock have an average target of 14.25, with a low estimate of 11 and a high estimate of 18. The average target predicts an increase of 718.97% from the current stock price of 1.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vor Biopharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 5 | 5 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +532.18% | Apr 23, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $12 | Buy | Reiterates | $12 | +589.66% | Mar 22, 2024 |
| Stifel | Stifel | Strong Buy Maintains $15 → $12 | Strong Buy | Maintains | $15 → $12 | +589.66% | Mar 21, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +532.18% | Mar 21, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $17 → $15 | Buy | Reiterates | $17 → $15 | +762.07% | Mar 21, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.45
from -1.75
EPS Next Year
-1.31
from -1.45
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 102.2M | 416.4M |
| Avg | n/a | n/a | n/a | 49.4M | 200.9M |
| Low | n/a | n/a | n/a | n/a | 9.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 743.4% |
| Avg | - | - | - | - | 306.8% |
| Low | - | - | - | - | -81.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.06 | -0.92 | -0.81 | -0.39 | 0.68 |
| Avg | -1.45 | -1.31 | -1.24 | -1.33 | -0.39 |
| Low | -1.76 | -1.58 | -1.52 | -1.89 | -1.90 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.